Shares of Evoke Pharma Inc. (NASDAQ:EVOK) were down 15.8% during mid-day trading on Wednesday . The company traded as low as $2.06 and last traded at $2.08, with a volume of 2,012,837 shares changing hands. The stock had previously closed at $2.47.

A number of analysts recently issued reports on EVOK shares. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a research report on Saturday, May 14th. Brean Capital reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Rodman & Renshaw reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Noble Financial downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Zacks Investment Research downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $14.34.

The firm’s market capitalization is $14.55 million. The stock has a 50-day moving average price of $6.59 and a 200 day moving average price of $4.81.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. On average, analysts anticipate that Evoke Pharma Inc. will post ($1.41) earnings per share for the current year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total value of $1,617,364.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of the company’s stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total value of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.